On 7 October 2024, we were pleased to launch the 46th edition of our policy magazine, Dementia in Europe, together with a supplement about clinical trials on dementia. The magazine was published to coincide with the 34th Alzheimer Europe Conference (#34AEC), which took place in Geneva, Switzerland, from 8-10 October. All delegates received a copy of the magazine and supplement in their conference bags.
The 34th Alzheimer Europe Conference (#34AEC) “New horizons – Innovating for dementia” took place at the Centre International de Conférences Genève (CICG), between 8 and 10 October 2024, attracting 963 delegates from 42 European countries. On the agenda were over 400 presenters (150 presenters for oral presentations, another 100 quick oral presentations and 240 poster presentations).
On 14 October, Alzheimer Europe published its response to the negative European Medicines Agency decision on lecanemab, in which we highlight concerns with health equity and autonomy and call for robust risk management that balances access to treatment with rigorous safety oversight.
We are pleased to welcome András Kulja MEP (Hungary) as a new member of the European Alzheimer’s Alliance (EAA) and to thank Romana Jerković MEP (Croatia) and Dainius Žalimas MEP (Lithuania) for accepting our invitation to act as Co-Chairs of the Alliance. As at the end of October, the EAA has 76 members from 21 EU Member States and the majority of political groups in the European Parliament.
Alzheimer Europe's 
On 7 October 2024, we were pleased to launch the 46th edition of our policy magazine, Dementia in Europe, together with a supplement about clinical trials on dementia. The magazine was published to coincide with the 34th Alzheimer Europe Conference (#34AEC), which took place in Geneva, Switzerland, from 8-10 October. All delegates received a copy of the magazine and supplement in their conference bags.
The 34th Alzheimer Europe Conference (#34AEC) “New horizons – Innovating for dementia” took place at the Centre International de Conférences Genève (CICG), between 8 and 10 October 2024, attracting 963 delegates from 42 European countries. On the agenda were over 400 presenters (150 presenters for oral presentations, another 100 quick oral presentations and 240 poster presentations).
On 14 October, Alzheimer Europe published its response to the negative European Medicines Agency decision on lecanemab, in which we highlight concerns with health equity and autonomy and call for robust risk management that balances access to treatment with rigorous safety oversight.
We are pleased to welcome András Kulja MEP (Hungary) as a new member of the European Alzheimer’s Alliance (EAA) and to thank Romana Jerković MEP (Croatia) and Dainius Žalimas MEP (Lithuania) for accepting our invitation to act as Co-Chairs of the Alliance. As at the end of October, the EAA has 76 members from 21 EU Member States and the majority of political groups in the European Parliament.